FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4207072910> ?p ?o ?g. }

• W4207072910 endingPage "S110" @default.
• W4207072910 startingPage "S109" @default.
• W4207072910 abstract "Abstract OBJECTIVE ABP 501 (AMGEVITA®) was the first approved biosimilar to adalimumab reference product (RP) by the European Medicines Agency and has been marketed in the European Union since 2018. Additional real-world data on its efficacy and safety, particularly for treating patients with inflammatory bowel disease (IBD), an indication approved on the basis of extrapolation, has the possibility of addressing barriers to utilization. METHODS This was a retrospective analysis of data collected between April and June 2021 from the Adelphi IBD Disease Specific Programme (DSP) covering ulcerative colitis (UC) and Crohn’s disease (CD) in Germany, France, Spain, Italy, and United Kingdom. Gastroenterologists provided data on demographics, clinical characteristics, treatment history, and treatment satisfaction. Patients had the option to complete the short IBD questionnaire (SIBDQ) aimed at measuring the burden of disease, work productivity and activity impairment (WPAI) questionnaire, and to indicate their assessment of treatment satisfaction. Descriptive analyses were conducted; continuous variables were reported as means or medians, categorical variables as number of patients and percentages. RESULTS 82 physicians reported data on 396 patients (189 UC and 207 CD): 239 initiated ABP 501 as first advanced therapy (AT) (initiators), 157 switched to ABP 501 from RP with no prior use of other AT (switchers) (Table). Median time from IBD diagnosis to initiation of ABP 501 was 13.9 months for initiators with median time on ABP 501 being 7.5 months at the time of data collection. Switchers previously received RP for a median of 14.1 months and had been on ABP 501 for a median time of 7.7 months since switching. The main reasons for switching from RP to ABP 501 were related to the potential to lower healthcare cost. At the time of reporting, more than two-thirds (67% initiators, 83% switchers) had mild disease, more than three-quarters were in clinical remission (74% initiators, 88% switchers), and a majority were in improving or stable disease status (96% initiators, 98% switchers). Mean SIBDQ scores (56 vs. 59) and overall work impairment (4.7% vs. 3.2%) were similar across initiators and switchers, respectively. Physicians and patients (&gt;90% each of initiators and switchers) reported being satisfied with current treatment with ABP 501. CONCLUSION ABP 501 was used as initial or continuing adalimumab therapy in the real-world setting to treat patients with IBD. At least three-fourths of patients currently on ABP 501 were in clinical remission, with a higher proportion in the switching group. Both physicians and patients reported very high levels of satisfaction with treatment." @default.
• W4207072910 created "2022-01-26" @default.
• W4207072910 creator A5025033411 @default.
• W4207072910 creator A5026054571 @default.
• W4207072910 creator A5027747345 @default.
• W4207072910 creator A5055574550 @default.
• W4207072910 creator A5060511880 @default.
• W4207072910 creator A5075854589 @default.
• W4207072910 creator A5077691071 @default.
• W4207072910 date "2022-01-22" @default.
• W4207072910 modified "2023-10-05" @default.
• W4207072910 title "REAL-WORLD UTILIZATION OF ADALIMUMAB BIOSIMILAR (ABP 501) IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN EUROPE" @default.
• W4207072910 doi "https://doi.org/10.1093/ibd/izac015.176" @default.
• W4207072910 hasPublicationYear "2022" @default.
• W4207072910 type Work @default.
• W4207072910 citedByCount "0" @default.
• W4207072910 crossrefType "journal-article" @default.
• W4207072910 hasAuthorship W4207072910A5025033411 @default.
• W4207072910 hasAuthorship W4207072910A5026054571 @default.
• W4207072910 hasAuthorship W4207072910A5027747345 @default.
• W4207072910 hasAuthorship W4207072910A5055574550 @default.
• W4207072910 hasAuthorship W4207072910A5060511880 @default.
• W4207072910 hasAuthorship W4207072910A5075854589 @default.
• W4207072910 hasAuthorship W4207072910A5077691071 @default.
• W4207072910 hasBestOaLocation W42070729101 @default.
• W4207072910 hasConcept C105639569 @default.
• W4207072910 hasConcept C126322002 @default.
• W4207072910 hasConcept C144024400 @default.
• W4207072910 hasConcept C144133560 @default.
• W4207072910 hasConcept C149923435 @default.
• W4207072910 hasConcept C1862650 @default.
• W4207072910 hasConcept C2778260677 @default.
• W4207072910 hasConcept C2779134260 @default.
• W4207072910 hasConcept C2780084366 @default.
• W4207072910 hasConcept C2780132546 @default.
• W4207072910 hasConcept C2780479503 @default.
• W4207072910 hasConcept C2910001868 @default.
• W4207072910 hasConcept C59491497 @default.
• W4207072910 hasConcept C71924100 @default.
• W4207072910 hasConceptScore W4207072910C105639569 @default.
• W4207072910 hasConceptScore W4207072910C126322002 @default.
• W4207072910 hasConceptScore W4207072910C144024400 @default.
• W4207072910 hasConceptScore W4207072910C144133560 @default.
• W4207072910 hasConceptScore W4207072910C149923435 @default.
• W4207072910 hasConceptScore W4207072910C1862650 @default.
• W4207072910 hasConceptScore W4207072910C2778260677 @default.
• W4207072910 hasConceptScore W4207072910C2779134260 @default.
• W4207072910 hasConceptScore W4207072910C2780084366 @default.
• W4207072910 hasConceptScore W4207072910C2780132546 @default.
• W4207072910 hasConceptScore W4207072910C2780479503 @default.
• W4207072910 hasConceptScore W4207072910C2910001868 @default.
• W4207072910 hasConceptScore W4207072910C59491497 @default.
• W4207072910 hasConceptScore W4207072910C71924100 @default.
• W4207072910 hasIssue "Supplement_1" @default.
• W4207072910 hasLocation W42070729101 @default.
• W4207072910 hasOpenAccess W4207072910 @default.
• W4207072910 hasPrimaryLocation W42070729101 @default.
• W4207072910 hasRelatedWork W1993762334 @default.
• W4207072910 hasRelatedWork W2571592438 @default.
• W4207072910 hasRelatedWork W2601143482 @default.
• W4207072910 hasRelatedWork W2904055208 @default.
• W4207072910 hasRelatedWork W2914532353 @default.
• W4207072910 hasRelatedWork W4220693647 @default.
• W4207072910 hasRelatedWork W4229777120 @default.
• W4207072910 hasRelatedWork W4380149278 @default.
• W4207072910 hasRelatedWork W4385064586 @default.
• W4207072910 hasRelatedWork W1540884887 @default.
• W4207072910 hasVolume "28" @default.
• W4207072910 isParatext "false" @default.
• W4207072910 isRetracted "false" @default.
• W4207072910 workType "article" @default.